False positive FDG-PET extensive diffuse abdominal tracer activity in a patient with CLL on whole-body 18FDG-PET/CT indicative of Ritcher's transformation

S. Mahmood; S. R. Martinez de Llano; S. Sajid

doi:10.1055/s-0037-1621120

Nuklearmedizin - NuclearMedicine, Inhaltsverzeichnis

Nuklearmedizin 2009; 48(06): N69-N70
DOI: 10.1055/s-0037-1621120

Case report

Schattauer GmbH

False positive FDG-PET extensive diffuse abdominal tracer activity in a patient with CLL on whole-body ¹⁸FDG-PET/CT indicative of Ritcher's transformation

S. Mahmood

¹Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

²Oncology Clinical Imaging, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

,

S. R. Martinez de Llano

¹Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

³MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital-Cyclotron Building, London, UK

,

S. Sajid

⁴Department of Medicine, The University of Chicago, Chicago, IL, USA

References
1 Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998; 25: 42-59.
2 Robertson LE, Pugh W, O'Brien S. et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993; 11: 1985-1989.
3 Armitage JO, Dick FR, Corder MP. Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia. Cancer 1978; 41: 422-427.
4 Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005; 103: 216-228.
5 Krause BJ, Beyer T, Bockisch A. et al. FDG-PET/CT in oncology. German Guideline. Nuklearmedizin 2007; 46: 291-301.
6 Karam M, Novak L, Cyriac J. et al. Role of fluor- ine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006; 107: 175-183.
7 Stergar H, Bockisch A, Eschmann SM. et al. Influence of PET/CT-introduction on PET scanning frequency and indications. Results of a multicenter study. Nuklearmedizin 2007; 46: 57-64.
8 La Fougère C, Pflüger T, Schneider V. et al. Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined ¹⁸F-FDG PET/CT. Nuklearmedizin 2008; 47: 37-42.
9 Bruzzi JF, Macapinlac H, Tsimberidou AM. et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006; 47: 1267-1273.
10 Divgi C. Imaging: staging and evaluation of lymphoma using nuclear medicine. Semin Oncol 2005; 32 (1 Suppl 1) S11-S18.
11 Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006; 47: 1326-1334.
12 Zissin R, Metser U, Hain D, Even-Sapir E. Mesenteric panniculitis in oncologic patients: PET-CT findings. Br J Radiol 2006; 79: 37-43.
13 Castellucci P, Zinzani P, Pourdehnad M. et al. ¹⁸F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005; 32: 749-756.
14 Sánchez Salmón A, Barandela Salgado J, Ruibal Morell A. PET in abdominal pathology: advantages and limitations. Abdom Imaging 2006; 31: 174-181.
15 O'Brien A, Del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307-318.